Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0248-8663(03)00270-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Movement Disorders that Occurred as Late Manifestations of Alzheimer's Disease Controlled by a Low dose of Carbamazepine.
Eur J Case Rep Intern Med
December 2024
Department of Geriatrics and Internal Medicine, Champmaillot Hospital, University Hospital, Dijon, France.
Introduction: According to the World Health Organization, 44 million people worldwide suffer from Alzheimer's disease. Abnormal movements are atypical symptoms of Alzheimer's disease.
Case Description: An 87-year-old woman, followed for Alzheimer's disease, experienced abnormal movements.
Neuroprotective potential of isofraxidin: Alleviating parkinsonian symptoms, inflammation and microglial activation.
J Cent Nerv Syst Dis
January 2025
School of Pharmacy, National Defense Medical Center, Taipei, Taiwan.
Background: Parkinson's disease (PD) is one of the most common neurodegenerative disorders. Previous research has confirmed that isofraxidin can reduce macrophage expression and inhibit peripheral inflammation. However, its effects on the central nervous system remain underexplored.
View Article and Find Full Text PDFOpicapone as adjunct to levodopa in treated Parkinson's disease without motor complications: A randomized clinical trial.
Eur J Neurol
January 2025
Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Background: Catechol-O-methyl transferase (COMT) inhibitors are routinely used to manage motor fluctuations in Parkinson's disease (PD). We assessed the effect of opicapone on motor symptom severity in levodopa-treated patients without motor complications.
Methods: This was a randomized, double-blind, 24-week, placebo-controlled study of opicapone 50 mg as adjunct to levodopa (NCT04978597).
Domain-Specific Prediction of Clinical Progression in Parkinson's Disease Using the Mosaic Approach.
Brain Behav
January 2025
Department of Neuroradiology, School of Medicine and Health, Technical University of Munich, Munich, Germany.
Purpose: Due to the highly individualized clinical manifestation of Parkinson's disease (PD), personalized patient care may require domain-specific assessment of neurological disability. Evidence from magnetic resonance imaging (MRI) studies has proposed that heterogenous clinical manifestation corresponds to heterogeneous cortical disease burden, suggesting customized, high-resolution assessment of cortical pathology as a candidate biomarker for domain-specific assessment.
Method: Herein, we investigate the potential of the recently proposed Mosaic Approach (MAP), a normative framework for quantifying individual cortical disease burden with respect to a population-representative cohort, in predicting domain-specific clinical progression.
Do the gait domains change in PD patients with freezing of gait during their 'interictal' period?
BMC Geriatr
January 2025
Department of Neurology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Objectives: Freezing of Gait (FOG) is one of the disabling symptoms in patients with Parkinson's Disease (PD). While it is difficult to early detect because of the sporadic occurrence of initial freezing events. Whether the characteristic of gait impairments in PD patients with FOG during the 'interictal' period is different from that in non-FOG patients is still unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!